SCHEMBL17484303

SCHEMBL17484303

CN(CO)C[C@@H]1CCCCN1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FDPS P14324 2/20 0.42
▸ GHSR Q92847 3/20 0.39
▸ CYP2D6 P10635 2/20 0.39
▸ MEN1 O00255 2/20 0.39
▸ LMNA P02545 2/20 0.39
▸ TP53 P04637 2/20 0.39
▸ KMT2A Q03164 2/20 0.39
▸ ALDH1A1 P00352 1/20 0.39
▸ CYP1A2 P05177 1/20 0.39
▸ TSHR P16473 1/20 0.39
▸ MLNR O43193 1/20 0.39
▸ ABCB11 O95342 1/20 0.39
▸ EGFR P00533 1/20 0.39
▸ FYN P06241 1/20 0.39
▸ CHRM2 P08172 1/20 0.39
▸ CHRM4 P08173 1/20 0.39
▸ HTR1A P08908 1/20 0.39
▸ CHRM5 P08912 1/20 0.39
▸ ADRA2A P08913 1/20 0.39
▸ ADORA3 P0DMS8 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9874777 0.85 FDPS (0.40) FDPSGHSRCYP2D6MEN1LMNA
SCHEMBL9875342 0.85 FDPS (0.40) FDPSGHSRCYP2D6MEN1LMNA
SCHEMBL4158323 0.82 CYP2D6 (0.40) FDPSGHSRCYP2D6MEN1LMNA
SCHEMBL9121250 0.82 CYP2D6 (0.40) FDPSGHSRCYP2D6MEN1LMNA
SCHEMBL9122889 0.79 CYP2D6 (0.44) FDPSGHSRCYP2D6MEN1LMNA
SCHEMBL1233909 0.79 CYP2D6 (0.44) FDPSGHSRCYP2D6MEN1LMNA
SCHEMBL10560492 0.79 CYP2D6 (0.44) FDPSGHSRCYP2D6MEN1LMNA
SCHEMBL18360656 0.79 FDPS (0.34) FDPSGHSR
SCHEMBL25562847 0.79 FDPS (0.34) FDPSGHSR
SCHEMBL9874402 0.79 FDPS (0.39) FDPSGHSRCYP2D6MEN1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2016015597-A1 COMPOUNDS AS CDK SMALL-MOLECULE INHIBITORS AND USES THEREOF SUNSHINE LAKE PHARMA CO., LTD. (CN) 2016-02-04 — — WO disclosed
Send feedback